Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

1 year ago 51
Read Entire Article
  1. Homepage
  2. Finance
  3. Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Related

Japan’s solid Q1 GDP faces reality check as Iran war threatens economy

Japan’s solid Q1 GDP faces reality check as Iran war threate...

25 minutes ago 0
Analog Devices in talks to buy Empower Semiconductor for $1.5 billion, Bloomberg News reports

Analog Devices in talks to buy Empower Semiconductor for $1....

25 minutes ago 0
Klaviyo’s SWOT analysis: stock navigates AI growth amid margin pressures

Klaviyo’s SWOT analysis: stock navigates AI growth amid marg...

25 minutes ago 0

Trending

1. ace bailey
2. knicks vs spurs
3. keke palmer
4. giannis antetokounmpo
5. stephen colbert last show
6. oakland athletics
7. bill simmons
8. angels baseball
9. zach neto
10. mariners score

Popular

College football by the odds: Vegas picks and preview of Ohio State vs. Notre Dame

College football by the odds: Vegas picks and preview of Ohi...

1 year ago 734
What is Tren de Aragua, the Venezuelan gang targeted by Trump?

What is Tren de Aragua, the Venezuelan gang targeted by Trum...

1 year ago 595
Taiwan slightly cuts 2025 GDP growth outlook amid Trump tariffs concern

Taiwan slightly cuts 2025 GDP growth outlook amid Trump tari...

1 year ago 461
Australian whose blood saved 2.4 million babies dies

Australian whose blood saved 2.4 million babies dies

1 year ago 459
What to do in Las Vegas this week: January 2-8

What to do in Las Vegas this week: January 2-8

1 year ago 407
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Sincity Press 2026. All rights are reserved